NCT04273191View on ClinicalTrials.gov

A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)

PHASE4WithdrawnINTERVENTIONAL

0

Timeline

Start Date

February 29, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions

Postpartum Depression

Interventions

DRUG

Brexanolone

Brexanolone will be initiated and administered per the USPI and the associated REMS.

Sponsors

Lead Sponsor

Sage Therapeutics

All Listed Sponsors

lead

Sage Therapeutics

INDUSTRY